title: Detection and assessment of co-association in inhalable drug particles using aerosol time-of-flight mass spectrometry.
abstract: Aerosol Time-of-Flight Mass Spectrometry (AToFMS) was used to examine co-association between two inhaled drugs, fluticasone propionate (FP) and salmeterol xinofoate (SX), in fine aerosolised particles emitted from Seretide(R)/Advair(R) inhaled combination products. Principal Component Analysis (PCA) was used to identify fragmentation patterns indicative of either pure or co-associated particles (particles containing both drugs). A third component of the particles emitted from dry powder inhalers (DPIs), lactose, gave only a very weak mass spectral signal and no interpretable data was acquired for this compound; however, it was not found to interfere with the detection of the two drug substances. High levels of co-association were found in the emitted doses from both pressurised metered dose inhaler (pMDI) and dry powder inhaler (DPI) products.
authors.affiliation: Novel Analytical Technologies, GlaxoSmithKline, Park Road, Ware SG12 0DP, UK. apn33849@googlemail.com
authors.forename: Anthony
authors.initials: A
authors.lastname: New
authors.forename: Dave
authors.initials: D
authors.lastname: Prime
authors.forename: Simeone
authors.initials: S
authors.lastname: Zomer
authors.forename: David
authors.initials: D
authors.lastname: Elder
authors.forename: Robert
authors.initials: R
authors.lastname: Donovan
authors.forename: Evelyn
authors.initials: E
authors.lastname: Freney
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols / Q000737:chemistry; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D000730:Androstadienes / Q000008:administration & dosage / Q000737:chemistry*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000737:chemistry; D004338:Drug Combinations; D000068298:Fluticasone; D000068297:Fluticasone-Salmeterol Drug Combination; D006801:Humans; D007785:Lactose / Q000032:analysis; D013058:Mass Spectrometry / Q000379:methods*; D036501:Metered Dose Inhalers; D015999:Multivariate Analysis; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D025341:Principal Component Analysis; D000068299:Salmeterol Xinafoate
chemical_list: D000336:Aerosols; D000730:Androstadienes; D001993:Bronchodilator Agents; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D007785:Lactose; D000420:Albuterol